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Abstract: We describe the multigram synthesis and in vivo efficacy studies of  
a donepezil‒huprine hybrid that has been found to display a promising in vitro multitarget 
profile of interest for the treatment of Alzheimer’s disease (AD). Its synthesis features as 
the key step a novel multigram preparative chromatographic resolution of intermediate 
racemic huprine Y by chiral HPLC. Administration of this compound to transgenic 
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CL4176 and CL2006 Caenorhabditis elegans strains expressing human Aβ42, here used as 
simplified animal models of AD, led to a significant protection from the toxicity induced 
by Aβ42. However, this protective effect was not accompanied, in CL2006 worms, by a 
reduction of amyloid deposits. Oral administration for 3 months to transgenic APPSL mice, a 
well-established animal model of AD, improved short-term memory, but did not alter brain 
levels of Aβ peptides nor cortical and hippocampal amyloid plaque load. Despite the clear 
protective and cognitive effects of AVCRI104P4, the lack of Aβ lowering effect in vivo 
might be related to its lower in vitro potency toward Aβ aggregation and formation as 
compared with its higher anticholinesterase activities. Further lead optimization in this 
series should thus focus on improving the anti-amyloid/anticholinesterase activity ratio. 
Keywords: disease-modifying anti-Alzheimer drugs; multitarget drugs; neuroprotection; 
animal models of Alzheimer’s disease; multigram preparative chromatographic resolution 
 
1. Introduction 
Alzheimer’s disease (AD) currently constitutes a huge human tragedy due to its devastating effects 
on the quality of life of patients, and its increasingly higher prevalence and mortality. AD currently 
affects some 44 million people worldwide and is among the top ten leading causes of death in 
developed countries, and the trend is that these figures will keep on increasing in the next decades [1]. 
The drugs marketed so far to combat AD were developed to alleviate the symptoms of the disease, 
i.e., the cognitive and functional decline mainly caused by a cholinergic deficit in the central nervous 
system (CNS). As long as more players in the neuropathogenesis of AD, placed upstream of the 
neurotransmitter deficits that originate AD symptomatology, have been known, intensive research has 
been conducted to develop new drugs able to modulate those upstream targets and, hence, the 
underlying mechanisms of the disease. A number of promising drug candidates have been developed in 
the past decade to separately hit one of the putative key players of AD neuropathogenesis, prominently 
the formation or the aggregation of the β-amyloid peptide (Aβ) [2,3]. However, none of these single-target 
disease-modifying agents has demonstrated to be effective and safe in clinical trials, so far. In this 
context, alternative approaches are worth of consideration in the pursuit of effective drugs that may 
prevent, stop or delay AD progression. An alternative approach, which is gaining adepts in the last 
years, is based on the consideration of AD as a pathological network where several protein targets of 
similar relevance are interconnected, leading to a robust system that cannot be perturbed by separate 
modulation of any single target [4]. The therapeutic strategy that follows from this novel conception of 
the disease is evident, i.e., the simultaneous modulation of several important targets of the disease 
network seems to be a more realistic option for tackling the neurodegenerative process of AD [5–9]. 
Indeed, this approach has proved successful in recent in vivo studies with some multitarget 
compounds such as memoquin [10] and IQM-622 [11] in different mouse models of AD, where these 
compounds have been shown to be able to address the underlying mechanisms of neurodegeneration. 
We have recently developed a new structural family of hybrid compounds, which were designed  
by combination of pharmacophoric moieties of two potent inhibitors of acetylcholinesterase (AChE), 
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namely donepezil and huprine Y [12]. The rationale behind this design was to enable interactions at 
different sites of a particular target, simultaneously affecting two important targets in the context of 
AD treatment. Thus, the novel donepezil‒huprine hybrids were decorated with structural motifs as to 
enable their simultaneous interactions at three different sites all along the 20 Å-deep catalytic gorge of 
the enzyme AChE [13], namely the active, midgorge and peripheral sites, which should lead to a 
potent cholinergic effect. On the other hand, this multiple-site binding to AChE was expected to lead 
to a disruption of the binding of the AChE peripheral site to Aβ [14,15], and hence, to an inhibition of 
the Aβ proaggregating action of AChE [16,17]. Indeed, in vitro these donepezil-huprine hybrids were 
endowed with both activities for which they had been rationally designed. Additionally, screening  
at other targets of interest for AD treatment revealed that these hybrids can also inhibit in vitro 
butyrylcholinesterase (BChE), Aβ self-aggregation and BACE-1, the enzyme that catalyzes the first 
and rate-limiting step of the proteolytic cleavage of the amyloid precursor protein (APP) to Aβ, 
thereby expanding the in vitro multitarget profile of these compounds. AVCRI104P4 (Scheme 1) 
emerged as the lead of this structural family, by virtue of its interesting in vitro multitarget profile 
(Table 1). 
 
Scheme 1. Reported low scale synthesis of AVCRI104P4 (route A) and envisaged 
alternative sequence (route B). 
  
Molecules 2015, 20 4495 
 
 
Table 1. In vitro and ex vivo biological profile of AVCRI104P4 relative to the parent 
compounds donepezil and huprine Y [12]. 
Compound hAChE IC50 nM hBChE IC50 nM BACE-1 IC50 µM 
Aβ Aggreg.  
% Inhibition  
at 10 µM a 
PAMPA-BBB  
Pe (10‒6 cm·s‒1) b  
(Prediction) 
Ex Vivo Studies c  
% Inhibition 
Brain AChE 
AVCRI104P4 2.61 349 11.0 29 11.4 (CNS+) 59% at 5 min d 
Donepezil 21.4 7273 11.3 <5 25.2 (CNS+) 73% at 5 min e 
(‒)-Huprine Y 0.43 247 Nd f 10.2 18.2 (CNS+) 97% at 20 min 
a [Aβ1‒42]/[inhibitor] = 5:1; b Permeability (Pe) results from the PAMPA-BBB assay [18], AVCRI104P4 
dissolved in PBS/EtOH 70:30, donepezil and (‒)-huprine Y dissolved in PBS/EtOH 80:20; c % Inhibition of 
OF1 mice brain AChE at the indicated time after i.p. administration of 10 µmol·kg‒1 of the compound versus 
untreated controls; d 46% at 20 min (unpublished results); e 68% at 20 min; f Not determined, 14% inhibition 
at 5 µM.  
It is generally believed that multitarget compounds should display similar in vitro potencies at their 
different biological targets, usually within one order of magnitude of each other, which might lead to  
a similar level of occupancy of those targets in vivo [19]. However, it has been suggested that the 
potencies at the different targets may not necessarily have to lie within such a narrow range, so that  
in vivo studies of a lead candidate may be very helpful to ascertain the adequate ratio of in vitro  
activities [19]. Thus, even though the two main in vitro activities of AVCRI104P4 might seem not 
properly balanced, with anticholinesterase activities in the nanomolar (AChE) to submicromolar 
(BChE) range and anti-amyloid activity (BACE-1) in the low micromolar range, in vivo testing of this 
compound was envisaged to definitely find out whether the different activities of this lead might arise 
also in vivo.  
Herein, we describe the synthesis at a multigram scale of AVCRI104P4, which involves as the key 
step a novel multigram preparative chromatographic resolution of the intermediate racemic huprine Y 
by chiral HPLC, and the in vivo efficacy studies of AVCRI104P4 in different animal models of AD,  
two transgenic Caenorhabditis elegans strains expressing Aβ42 (CL4176 and CL2006) as simplified 
invertebrate models, and transgenic APPSL mice, as a well-established animal model. Particularly, the 
protective effects of AVCRI104P4 against the paralysis induced in CL4176 by the oligomeric 
production of Aβ1‒42 and in CL2006 by the constitutive expression of Aβ3‒42, leading to both 
oligomeric and fibrillar protein deposition, have been assessed. Moreover, the behavioural effects of 
AVCRI104P4 in APPSL transgenic mice orally treated for 3 months, as well as its effects on Aβ levels 
in cerebrospinal fluid (CSF) and brain homogenates, and on the amyloid load in cortex and 
hippocampus have been also determined. 
2. Results and Discussion 
2.1. Synthesis of AVCRI104P4 
AVCRI104P4 had been previously synthesized at a centigram scale (64 mg) [12]. However, the 
planned in vivo studies required multigram amounts of this compound, thereby making it necessary  
a scale-up the synthesis. 
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The low scale synthesis of AVCRI104P4 involved the preparative chromatographic resolution of 
racemic huprine Y (1), the synthesis of the donepezil-derived chloropropylpiperidine 2, and the final 
coupling of enantiopure (–)-(7S,11S)-huprine Y with 2 (route A in Scheme 1) [12]. However, because 
purification of AVCRI104P4 by standard silica gel column chromatography had been a quite difficult, 
low yield, and tedious task in the low scale synthesis [12], a quite attractive option for the scale-up 
synthesis might involve the direct preparative chiral chromatography of multigram amounts of the  
crude racemic final compound, inasmuch as separation of AVCRI104P4 from its enantiomer and from 
unreacted starting materials or other byproducts formed in the reaction might be done at once, thereby 
avoiding a previous achiral chromatographic step (route B in Scheme 1). Thus, a crucial decision 
before starting the scaled up synthesis of AVCRI104P4 was the step at which the chromatographic 
resolution should be done. 
In this context, samples of pure racemic 1, pure racemic 3, and crude racemic 3 were subjected to  
an exhaustive screening in liquid and supercritical fluid chromatography (LC and SFC), in order to 
identify suitable preparative methods and subsequently compare them. 
A number of chiral stationary phases (CSPs) were able to separate both racemates for analytical 
purposes. Nevertheless, for the preparative application, the first important preliminary observation was 
the limited solubility of the three samples in many organic solvents. Therefore, the screening of mobile 
phases had to be dictated by the solubility, otherwise, the preparative resolution would be inefficient. 
Dichloromethane (DCM), EtOAc and THF mixtures were chosen as preferred options and this was 
conditioning the type of CSPs to be used. 
The three samples were screened on polysaccharide-derived columns, having the chiral selector 
immobilized onto the silica backbone. Those phases (CHIRALPAK IA, IB and IC) were combining  
a high loading capacity with the possibility of using the above mentioned solvents as mobile phases 
and/or injection solvents [20–22]. Separations for the enantiomeric pairs were identified in LC and 
SFC mode, however, LC seemed to be better adapted to these molecules. 
One of the main advantages of SFC at preparative scale is the possibility of working in CO2 
mixtures with a relatively low percentage of co-solvent (usually 10%–20%). However, both 1 and 3 
were rather retained in SFC mode, so that higher co-solvent percentages were needed and solubility 
was an issue. Therefore, the SFC option was quickly discarded. 
Taking into account all these elements, the screening undertaken in LC was reviewed and put into 
perspective. The best option found was the resolution of the racemic precursor, huprine Y, (±)-1, on 
CHIRALPAK IC with a mobile phase composed by a DCM/i-PrOH mixture (details may be seen in 
the Experimental Section). The main reasons for such a decision were: (i) the impossibility of isolating  
(–)-(7S,11S)-3 (AVCRI104P4) in a single chromatographic step from the crude material and (ii) the 
low solubility of the molecules. 
In Figure 1A the initially identified resolution of the peaks in the crude material at analytical level 
(with peak identification) can be found. Such conditions involved 50% of n-heptane in the mobile 
phase and the sample was only sparingly soluble. It was necessary then optimizing the method by 
avoiding the alkane and modulating retention, as well as recognition with a DCM/i-PrOH mixture (see 
chromatogram of the crude in Figure 1B). The combination of DCM with other solvents such as THF 
was tested, but found to be less adapted. In DCM/i-PrOH, (–)-3 (AVCRI104P4) and (–)-1 ((–)-huprine Y)) 
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co-elute and the two enantiomers of 3 hardly reach baseline separation. Therefore, it seemed that the 
preparative resolution of racemic huprine Y, (±)-1, was the best option (Figure 1C). 
 
Figure 1. Chromatographic separation by HPLC of (A) crude mixture of racemic 1 and 3 
on CHIRALPAK IC (5 µm, 250 × 4.6 mm) in n-heptane/DCM/EtOH/DEA 50:50:1:0.1,  
2 mL/min, 25 °C; (B) crude mixture of racemic 1 and 3 on CHIRALPAK IC (20 µm,  
250 × 4.6 mm) in DCM/i-PrOH/DEA 95:5:0.1, 1 mL/min, 25 °C; (C) Racemic 1 on 
CHIRALPAK IC (20 µm, 250 × 4.6 mm) in DCM/i-PrOH/DEA 95:5:0.1, 1 mL/min, 25 °C.  
Intermediate racemic huprine Y (±)-1, and chloroderivative 2 were synthesized at multigram scale 
following the described procedures [12,23–27], with some necessary modifications due to the scale of 
work (see Supplementary Materials). 
At this point, taking into account the results of the chromatographic screening (Figure 1), we 
undertook the multigram chromatographic resolution of intermediate huprine Y, (±)-1. As outlined in 
Scheme 1, we had performed the low scale synthesis of enantiopure huprines by preparative 
chromatographic resolution of the corresponding racemates, using a medium pressure liquid 
chromatography (MPLC) equipment, microcrystalline cellulose triacetate as the chiral stationary phase 
and 96% EtOH as the eluent [26]. Indeed, we had separated (–)-(7S,11S)-huprine Y (189 mg, >90% 
ee) and (+)-(7R,11R)-huprine Y (140 mg, >80% ee) using this methodology, after four successive 
injections of the racemic compound (1 × 100 mg + 3 × 150 mg) [26]. The enantiomeric excesses were 
subsequently upgraded upon conversion into the corresponding hydrochloride salts followed by 
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recrystallization. Obviously, this laboratory equipment and scale of work were by far insufficient to 
perform the chromatographic resolution of decagram amounts of racemic huprine Y. 
The large scale chromatographic resolution of huprine Y was carried out by preparative HPLC on  
a 66 g batch (scale factor ×120 relative to the low scale synthesis) using a CHIRALPAK IC column 
(cellulose tris(3,5-dichlorophenylcarbamate)) and a mixture DCM/i-PrOH/DEA 90:10:0.1 as the 
eluent, to yield >99% ee (–)-(7S,11S)-huprine Y (28.5 g) and (+)-(7R,11R)-huprine Y (24.7 g) (Scheme 2). 
The estimated throughput would be 72 g of (–)-(7S,11S)-huprine Y per day using a 250 × 110 
mm-column in a 24/24 h process by batch chromatography (144 g of racemate processed), i.e., 96 g of 
racemate per kg of CSP and day. If such a method were translated to continuous chromatography 
(Simulated Moving Bed, SMB) it would involve about 300 g of pure enantiomer per kg of CSP and day. 
Overall, the multigram chromatographic resolution of huprine Y was performed not only with the 
necessary much higher loading capacity but also with higher enantiopurity and resolution efficiency, so that 
amounts of both enantiomers >150-fold larger than those obtained in the low scale synthesis were obtained. 
 
Scheme 2. Novel multigram HPLC resolution of huprine Y and scale-up synthesis of AVCRI104P4. 
Finally, reaction of enantiopure (–)-(7S,11S)-huprine Y (3.34 g, >99.8% ee) with chloroderivative 2 
in the presence of KOH in DMSO afforded AVCRI104P4 (2.94 g) in significantly higher yield than in 
the low scale procedure (42% isolated yield, after silica gel column chromatography purification vs. 
15% isolated yield in the low scale synthesis, Scheme 2). After several runs of this reaction, a total 
amount of 14 g of AVCRI104P4 was finally obtained, which allowed us to undertake the planned  
in vivo studies. 
2.2. In Vivo Studies in C. elegans 
Before testing AVCRI104P4 in a mouse model of AD, we conducted some in vivo studies in  
a simplified invertebrate model, namely in Caenorhabditis elegans. This nematode offers a number of 
advantages such as a short lifecycle, high reproduction profile, experimental flexibility, and ease to 
knockdown gene expression, among others, which has prompted the creation of different strains that 
express amyloidogenic proteins involved in different neurodegenerative disorders [28]. Thus, 
transgenic C. elegans AD models have been used to study pathogenic pathways and alterations of gene 
expression induced by Aβ [29,30], and, recently, also for the evaluation of the neuroprotective and 
anti-amyloidogenic effects of some multitarget anti-Alzheimer compounds [31–33]. 
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Herein, we determined the ability of AVCRI104P4 to protect from the toxicity induced by human Aβ42 
expression and accumulation, which results in plaque deposits similar to those observed in the brain of 
AD patients [34]. To this end, the transgenic C. elegans strain CL2006, constitutively expressing 
human Aβ3–42 in the body wall muscle cells [35,36], was here used. This strain is characterized by a 
progressive and age-related reduction of the motility due to the expression of Aβ3–42 which results in 
the formation of both fibrils and oligomers [36]. The CL4176 transgenic C. elegans strain, in which the 
human Aβ1–42 expression was induced by increasing the temperature of culture, was also used. In this 
strain, the paralysis phenotype is specifically associated with the deposition of oligomers in their 
muscle cells without the formation of amyloid aggregates [36,37]. Previous results obtained in CL4176 
nematodes treated with anti-amyloidogenic tetracyclines supported the toxic role of oligomers [36–38]. 
CL802 nematodes, which do not express the Aβ transgene [34], were used as controls. 
In CL2006 worms the administration of 100 µM AVCRI104P4 for 24 h caused a little, albeit 
significant, reduction of 26.5% of the Aβ3–42-induced paralysis, significantly lower than that occurring 
with 100 µM tetracycline (74.6% reduction of paralysis) (Figure 2A). The feeding of CL802 worms 
with 100 µM AVCRI104P4 for 24 h did not modify their paralysis (2.3% ± 1.0% and 2.7% ± 0.9% of 
percentage of paralyzed worms for CL802 nematodes fed with vehicle and AVCRI104P4, 
respectively), with this result being indicative of the fact that this compound did not induce any 
unspecific and/or toxic effect in control nematodes. 
We then investigated the effect of AVCRI104P4 on the degree of Aβ amyloidosis by evaluating the 
number of aggregate deposits in the head region of CL2006 transgenic worms. To this end, synchronized 
worms were grown at 16 °C for 72 h and treated with either vehicle or AVCRI104P4 (100 µM,  
100 µL/plate) for 24 h. Nematodes were then stained with the X-34 dye, specifically recognizing  
β-amyloid deposits [36]. AVCRI104P4 did not reduce the X-34 positive spots (Figure 2B), which 
indicated that the protective effect of the compound cannot be ascribed to its ability to affect Aβ fibril 
deposition. The dot blot analysis performed on worm lysates with the WO2 total Aβ-specific antibody 
(Figure 2C) indicated that there were no differences in the Aβ-immunoreactive signal between worms 
treated for 24 h, with vehicle or 100 µM AVCRI104P4. These data indicate that the ability of 
AVCRI104P4 to counteract Aβ toxicity was not linked to its ability to modify the amount of Aβ 
produced and/or degraded by transgenic nematodes. 
The effect of AVCRI104P4 on CL4176 worms was also investigated since this strain represents a 
convenient model to specifically study the in vivo effects of Aβ oligomers and to screen for potential 
anti-oligomer compounds [35,36]. Administration of 100 µM AVCRI104P4, 18 h after the rise of 
temperature, reduced the paralysis by 47.5%, similarly to 100 µM tetracycline (45.4% reduction of 
paralysis) (Figure 3A). Aldicarb, an AChE inhibitor, did not exert any protective action (Figure 3A), 
indicating that the protective activity of AVCRI104P4 against the toxicity exerted by oligomeric Aβ 
was specific and unrelated to the inhibition of AChE. In addition, AVCRI104P4 protected CL4176 
nematodes from the Aβ-induced paralysis in a dose-dependent manner (Figure 3B). The drug 
concentration that inhibited paralysis by 50% (IC50) was 34.0 ± 1.2 µM (n = 100 worms/group,  
mean ± SE), similar to that obtained for tetracycline (39.9 ± 1.5 µM) [36]. 
The protective effect of AVCRI104P4 in CL4176 worms was not associated to its ability to modify 
the amount of Aβ produced by transgenic nematodes, as indicated by the dot blot analysis performed 
with the WO2 total Aβ-specific antibody (Figure 3C). These results indicate that the protective effect 
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of AVCRI104P4 against Aβ toxicity was greater in CL4176 than in CL2006 nematodes, suggesting 
that this drug may exert its activity against the oligomeric assemblies of Aβ, without affecting amyloid 
plaque deposition and independently from its AChE inhibitory activity. 
 
Figure 2. Effect of AVCRI104P4 administration on the paralysis of CL2006 nematodes 
and Aβ deposition. (A) Percentage of CL2006 paralyzed worms treated with AVCRI104P4. 
Nematodes were treated for 24 h with 100 µM AVCRI104P4 or 100 µM tetracycline 
(positive control) and the number of nematodes that did not move was scored. Data from 
three independent experiments (n = 100, per group) are indicated as % ± S.D. of paralyzed 
nematodes to worms treated with vehicle. * p < 0.05 and ** <0.01 vs. vehicle-treated 
CL2006 nematodes and ° p < 0.05 vs. CL2006 worms treated with tetracycline (One-way 
ANOVA test); (B) X-34 positive amyloid deposits in CL2006 worms treated with vehicle 
or 100 µM AVCRI104P4. Synchronized CL2006 nematodes were treated with vehicle or 
100 µM AVCRI104P4 for 24 h, amyloid plaques were stained with X-34 dye and 
visualized at short wavelength excitation. Scale bar 20 µm. Amyloid deposits in the 
anterior area of worms, indicated with red arrows, were quantified in nematodes treated 
with vehicle (n = 20) or 100 µM AVCRI104P4 (n = 20), by counting the number of X-34 
positive spots; (C) Effect of 100 µM AVCRI104P4 administration on total Aβ in CL2006 
worms. Representative dot blot of total Aβ (WO2) on lysates (5 µg) of CL2006 transgenic 
worms treated with vehicle or 100 µM AVCRI104P4 for 24 h.  
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Figure 3. Effect of AVCRI104P4 on the paralysis of CL4176 worms. (A) Percentage of 
paralyzed CL4176 and CL802 worms fed with 100 µM AVCRI104P4, 100 µM aldicarb, or 
100 µM tetracycline 18 h after the temperature increase. Paralysis was evaluated 42 h after 
the temperature rise. Data from three independent experiments (n = 100, per group) are 
indicated as % ± S.D. of paralyzed nematodes to worms treated with vehicle. ** p < 0.01 
vs. vehicle-treated CL4176 nematodes (One-way ANOVA test); (B) Dose-dependent 
protective effect of AVCRI104P4 on the paralysis of CL4176 worms. The transgene 
expression was induced in synchronized worms after 54 h at 16 °C, by raising the 
temperature to 24 °C. Nematodes were fed with different concentrations of AVCRI104P4 
(5–300 µM, 100 µL/plate) 18 h after raising the temperature. The number of paralyzed 
worms was scored 42 h after the temperature rise. Data from three independent 
experiments (n = 100, per group) are indicated as % ± S.D. of paralyzed nematodes to 
worms treated with vehicle; (C) Effect of 100 µM AVCRI104P4 administration on total 
Aβ in CL4176 worms. Representative dot blot of total Aβ (WO2) on lysates (5 µg) of 
CL4176 transgenic worms treated with vehicle or 100 µM AVCRI104P4 as described.  
2.3. In Vivo Studies in Transgenic APPSL Mice 
The effects of AVCRI104P4 on cognition and amyloid pathology were evaluated in vivo in a  
well-established animal model of AD, namely in APPSL transgenic mice. These transgenic mice 
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develop early and progressive amyloid plaque deposition in cortex and hippocampus as well as 
cognitive impairment, thereby being widely used as preclinical animal models of AD. Twenty-four 
hAPPSL transgenic animals were treated orally with vehicle only or AVCRI104P4 daily for 3 months. 
Starting with a dose of 10 mg/kg of AVCRI104P4, the treatment dose was increased in a staggered 
manner, i.e., weekly + 5 mg/kg, up to a final dosage of 40 mg/kg per day. 
2.3.1. Behavioral Studies 
The Morris Water Maze (MWM) was performed at the end of the treatment period to evaluate the 
effects of AVCRI104P4 on cognition. During the last week of treatment, we planned the evaluation of 
the spatial navigation learning and memory of animals by assessing the escape latency (the time (s) the 
mice needed to find the hidden platform and therefore to escape from the water), the swim length (the 
length of the trajectory (m) to reach the target), the swim speed (calculated quotient of swim length 
and escape latency) and the average distance to the target zone (m), as well as the number of target 
crossings and the abidance in the target quadrant during the probe trial. On the first MWM training day 
(day -7), some compound treated animals had problems to keep their head above the water, which 
might be ascribed to an overdosing of AVCRI104P4. Despite this handicap, AVCRI104P4 treated 
animals performed significantly better in terms of escape latency and swim length compared to vehicle 
treated controls. Indeed, animals treated with AVCRI104P4 found the hidden platform in a 
significantly shorter time (Figure 4A) and needed a significantly shorter way to find the hidden 
platform (Figure 4B) than animals receiving vehicle only. These results indicated a clear improvement 
of the short-term memory upon treatment with AVCRI104P4. 
After a washout period of 5 days, the MWM test was repeated. Learning curves of days 1 to 4 of the 
postponed MWM training phase are depicted in Figure 4. During the main training phase, animals of 
both groups showed typical declining learning curves in terms of escape latencies and swimming 
paths. However, mice that had been treated with AVCRI104P4, which had shown improved short-term 
memory on the first MWM training day (day -7), did not show significantly improved spatial learning 
capabilities relative to controls after the washout period, i.e., in the absence of treatment, neither on 
day 1 nor on the following days (Figure 4A,B, and Figures S1 and S2, Supplementary Materials). 
Similarly, no significant differences between treatment groups were detected when calculating the 
swimming speed (Figure 4C), the time spent in the target quadrant where the platform was hidden 
(abidance) and the number of target zone crossings (Figure 4D). 
Thus, AVCRI104P4 treated animals started with significant lower escape latency and shorter way to 
find the hidden platform on training day -7, when training was assessed short after the last application 
of 40 mg/kg AVCRI104P4, but its clear cognitive effects disappeared from training day 1 onwards, 
after the washout period, likely because these mice did not receive any compound for 5 days. 
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Figure 4. Graph represents (A) the latency to escape from the water (escape latency);  
(B) the swimming path to escape from the water (swim length); (C) the swim speed; and 
(D) the abidance in the target quadrant and number of target zone crossings in the MWM 
of hAPPSL transgenic animals treated with vehicle only (group A, orange) or AVCRI104P4 
(group B, green) for 3 months. Data are presented as mean ± SEM for each treatment 
group and day. Statistical significant differences were detected on the very first training 
day (-7) using Mann-Whitney test (for (A)) or unpaired t-test (for (B)). * indicates p < 0.05. 
** indicates p < 0.01. No statistical significant differences were detected for (C) and (D). 
2.3.2. Biochemistry and Histology 
Aβ38, Aβ40, and Aβ42 levels were measured with an immunosorbent assay in CSF samples as well 
as in two brain homogenate preparations of transgenic mice, in which brain proteins from the left 
hemisphere of transgenic animals were extracted with diethylamine (DEA), which solubilizes non-plaque 
associated Aβ such as monomeric to oligomeric structures or with formic acid (FA), which dissolves 
the total Aβ in the brain homogenates including plaques. Also, amyloid load was visualized with 6E10 
antibody and thioflavin S (ThioS) staining and the signal was quantitatively analyzed in terms of the 
number of plaques, their total surface area, and their average size, both in the cortex and hippocampus. 
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Unfortunately, treatment with AVCRI104P4 did not alter Aβ38, Aβ40, and Aβ42 levels, neither in 
the CSF nor in DEA and FA brain homogenate preparations (Figure S3, Supplementary Materials), nor 
the number, area and mean size of 6E10 or ThioS objects in cortex and hippocampus (Figures S4–S6, 
Supplementary Materials) compared to vehicle treated controls. Similarly, plaque morphology, 
conformation of diffusely aggregated 6E10 immunoreactive amyloid and dense ThioS positive cores, 
and overall intracellular somal amyloid labeling was in general comparable between vehicle and 
AVCRI104P4 treatment groups (Figures S7‒S9, Supplementary Materials). 
Thus, contrary to our expectations, the moderately potent BACE-1 inhibitory activity observed  
in vitro for AVCRI104P4 did not result in any anti-amyloidogenic effect in vivo in hAPPSL transgenic 
mice. Conversely, its potent in vitro anti-cholinesterase activity leads to a clear cognitive enhancing 
effect in transgenic mice, which disappears in the absence of treatment. All together, the results 
obtained in the in vivo efficacy studies point to a purely cholinergic but non disease-modifying effect 
of AVCRI104P4, thereby highlighting the need to improve its in vitro anti-amyloid/anticholinesterase 
activity ratio in future lead optimization. 
2.4. Hepatotoxicity Studies in HepG2 Cells 
The huprine Y moiety of AVCRI104P4 is structurally related to tacrine, the first approved  
anti-Alzheimer drug which was withdrawn from the market due to its hepatotoxic effects. Despite the 
large number of tacrine-based multitarget compounds or structurally related derivatives that are being 
developed, very few reports about their potential hepatotoxicity can be found in the literature. To 
address this issue in this work, the effects of AVCRI104P4 on cell viability and cytotoxicity were 
determined by MTT and LDH assays in HepG2 cells, a human liver hepatocellular carcinoma cell line, 
and compared with those produced by tacrine. HepG2 cells were incubated with rising dose 
concentrations of AVCRI104P4 and tacrine (0, 0.03, 0.1, 0.3, 0.8, 2.5, 7.4, 22.2, 66.7, and 200 µM). 
HepG2 cells showed a cytotoxic response to increasing dose concentrations of AVCRI104P4, which 
exhibited EC50 values of 8.8 and 9.7 µM in the MTT and LDH assays, respectively (Figure 5). In the 
case of tacrine, minor toxic effects started at concentrations higher than 66.7 µM but its EC50 values 
could not be determined since toxic concentrations were beyond the indicated concentration range. 
Hence, notwithstanding the apparent lack of toxicity of other huprine derivatives in chronic in vivo 
studies in different mouse models, we have found that AVCRI104P4 is more toxic to HepG2 cells than 
tacrine itself. Of note, similar results have been found for bis(7)-tacrine, an heptamethylene-linked 
dimer of tacrine under preclinical development that features a similar multitarget profile to that of 
AVCRI104P4 [39], for which hepatotoxicity in mice [40] and a higher cytotoxicity than that of tacrine 
in Caco-2 cells [41] have been recently reported. 
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Figure 5. AVCRI104P4 and tacrine dose response in HepG2 cells. HepG2 cells were 
treated with AVCRI104P4 and tacrine at the indicated concentrations for 24 h. Cell 
viability and cellular toxicity were determined according to MTT and LDH assays, 
respectively. Values are shown as mean ± SEM (n = 6). 
3. Experimental Section 
3.1. Synthesis of AVCRI104P4 
3.1.1. Chromatographic Screening 
The screening was performed on CHIRALPAK IA, CHIRALPAK IB and CHIRALPAK IC  
(250 × 4.6 mm i.d., 5 μm) supplied by Daicel Corporation (Tokyo, Japan) in LC and SFC. Flow rates 
in LC were set at 1 or 2 mL/min (depending on retention) and temperature at 25 °C. The SFC 
screening was performed with MeOH, EtOH, and i-PrOH as co-solvents in CO2 and extended to other 
polysaccharide-derived columns. The LC screening covered n-heptane mixtures with alcohols, THF, 
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EtOAc, DCM, as well as pure acetonitrile and alcohols, with a number of combinations to optimise 
selectivity, retention and solubility. Optimisations were performed on the corresponding 20 μm materials. 
3.1.2. Chromatographic Resolution of (±)-Huprine Y at Preparative Scale 
Racemic huprine Y (66 g) was resolved into its two enantiomers using DCM/i-PrOH/DEA 90:10:0.1 
as the mobile phase. The chiral stationary phase was ca. 1.5 Kg of CHIRALPAK IC (20 μm), available 
from Daicel Corporation, packed into a 250 × 110 mm column. (–)-(7S,11S)-Huprine Y, (–)-(7S,11S)-1, 
was the first eluted enantiomer with this chromatographic method and its enantiomeric excess was 
>99.8%. Evaporation to dryness of the solvent yielded a thick oily material, which could be 
transformed into a solid by subsequent dissolution in DCM and evaporation. A total amount of 28.5 g 
of (–)-(7S,11S)-1 was isolated as a brown amorphous powder and used for the next reaction without 
further purification. The non-target (second eluting peak, (+)-(7R,11R)-1, 24.7 g) was also recovered at 
high % ee (99.4%) to keep the overall high recovery. 
3.1.3. (–)-(7S,11S)-3-Chloro-12-[(3-{4-[(5,6-dimethoxyindan-2-yl)methyl]piperidin-1-yl}propyl) 
amino]-6,7,10,11-tetrahydro-9-methyl-7,11-metanocycloocta[b]quinoline, AVCRI104P4  
[(–)-(7S,11S)-3] 
A suspension of (–)-huprine Y, (–)-(7S,11S)-1 (>99.8% ee, 3.34 g 11.7 mmol) and finely powdered 
KOH (85% purity, 3.90 g, 58.5 mmol) in anhyd. DMSO (48 mL) was stirred, heating every 10 min 
approximately with a heat gun for 1 h and at room temperature for an additional 1 h, and treated 
dropwise with a solution of crude 2 (5.00 g of a crude that could contain a maximum of 14.1 mmol of 
2, see Supplementary Materials) in anhydrous DMSO (40 mL) (previously warmed at 70 °C). The 
reaction mixture was stirred at room temperature for 3 days, diluted with H2O (150 mL), and 10 N 
NaOH (100 mL), and extracted with DCM (3 × 200 mL). The combined organic extracts were washed 
with H2O (2 × 200 mL), dried over anhydrous Na2SO4, and evaporated under reduced pressure to give 
a brown solid (10.9 g), which was purified through column chromatography (35–70 μm silica gel, 
EtOAc/hexane/Et3N 50:50:0.2), affording successively unreacted (–)-huprine Y (579 mg) and 
AVCRI104P4 (2.94 g, 42% yield). The IR, 1H- and 13C-NMR data coincided with those previously 
reported [12]; Anal. calcd for C37H46ClN3O2·2HCl·1.75H2O: C 63.06%, H 7.37%, N 5.96%, Cl 
15.09%, found: C 63.16%, H 7.33%, N 5.49%, Cl 14.80%. After several runs of this reaction, a total 
amount of 14 g of AVCRI104P4 was obtained. 
3.2. In Vivo Studies in Caenorhabditis elegans 
3.2.1. C. elegans Strains 
CL2006, CL4176 and the control CL802 transgenic strains were obtained from the Caenorhabditis 
Genetic Center (University of Minnesota, Minneapolis, MN, USA) [34,42]. CL2006 constitutively 
expresses Aβ3–42 in the body-wall muscles, while Aβ1–42 was produced in muscle cells of CL4176 
in a temperature-inducible manner. Nematodes were grown at 16 °C on solid Nematode Growth 
Medium (NGM) seeded with E. coli (OP50) for food. Age-synchronized animals were prepared as 
already described [34,42] and day 1 synchronized worms were cultured on fresh NGM plates at 16 °C. 
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3.2.2. Paralysis Assay 
The paralysis assay was performed in the CL4176 and CL802 worms as already described [35,36] 
Transgene expression was induced after 54 h of growth at 16 °C by raising the temperature from 16 to 
24 °C. Eighteen hours after the temperature shift (L3 larval stage) nematodes were fed with different 
concentrations of AVCRI104P4 (5–300 µM, 100 µL/plate, 100 worms/plate) or 100 µM aldicarb. The 
paralysis of worms was determined 42 h after the temperature raise by scoring nematodes that did not 
move. Fifty µM tetracycline (Fluka, Buchs, Switzerland) administered 18 h after temperature rise was 
used as positive control. Synchronyzed CL2006 worms were fed, at L3 larval stage, with 100 µM 
AVCRI104P4 (100 µL/plate, 100 worms/plate) and the number of nematodes paralyzed was scored 24 h 
later. Tetracycline was administered as a positive control. 
3.2.3. Aβ Expression 
Transgenic CL2006 and CL4176 worms treated with vehicle or 100 µM AVCRI104P4 were 
processed as previously described [36]. The proteins were precipitated overnight with MeOH (1:4 v/v) 
at −20 °C, before being resuspended in loading buffer and then spotted (5–10 µg) onto nitrocellulose 
membranes (Merck Millipore, Darmstadt, Germany). Total protein visualization on the blotted membranes 
was performed by using 0.1% Ponceau Red solution (Sigma Aldrich, Saint Louis, MO, USA). Anti-Aβ 
mouse monoclonal antibody (1:1000, Clone WO2, Merck Millipore) and peroxidase-conjugated  
anti-mouse IgG (1:5000, Sigma) were used as the primary and secondary antibodies, respectively. 
Mean volumes of immunoreactive and Red Ponceau dyed spots were analyzed (Progenesis SameSpots 
software 4.0, Nonlinear Dynamics Limited Keel House, Newcastle upon Tyne, UK; Nonlinear 
Dynamics, Newcastle upon Tyne, UK) and the mean values of volume of immunoreactive spot/volume 
of total Ponceau dyed proteins ± SD were calculated. 
3.2.4. Staining of β-Amyloid 
Treated and non-treated fixed CL2006 worms [36] were stained with X-34 (1.0 mM) in Tris-HCl  
(10 mM) for 4 h at room temperature and at pH 8.0 [36,43]. The samples were destained and then 
observed with a IX-71 Olympus inverted fluorescence microscope, acquiring the images with a CCD 
camera. Quantification of amyloid burden in the anterior area of vehicle- and AVCRI104P4-treated 
nematodes (n = 20 per group) was carried out through the number of X-34 positive spots and the ratio 
Aβ deposits/anterior area was calculated. 
3.2.5. Statistical Analysis 
The effects of AVCRI104P4 on nematodes were compared with those of vehicle by standard  
tests (independent Student’s t-test or One-way ANOVA test) and GraphPad Software (Prism version 
4.0 for Windows, San Diego, CA, USA) was used to calculate the IC50 values, taking p values < 0.05 
as statistically significant. 
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3.3. In Vivo Studies in Transgenic APPSL Mice 
3.3.1. Animals and Treatment 
Male APPSL transgenic mice were housed as previously described [44], i.e., in individual ventilated 
cages, with constant 12 h light/dark cycle, at 24 °C and 40%–70% humidity, and providing standard 
rodent chow (Altromin, Lage, Germany) and tap water ad libitum. Animals were maintained in the 
fully AAALAC accredited QPS Austria animal facility under standardized conditions. Animal studies 
conformed to the Austrian guidelines for the care and use of laboratory animals (BGBl. 501/1989 in 
the appropriate valid version) and were approved by the Styrian Government, Austria (FA10A-78 Jo 
85-2011). Twenty four mice at an age of 6 months (±2 weeks) were orally treated via gavage with 
vehicle or 40 mg/kg/day of AVCRI104P4 daily for 3 months (n = 12 each group). Eight animals were 
kept in reserve. 
3.3.2. Behavioural Studies 
The Morris Water Maze (MWM) was performed to assess spatial learning at the end of the 
treatment period. The MWM consisted of a white circular pool of a diameter of 100 cm, filled with tap 
water at a temperature of 21 ± 2 °C. Each mouse had to perform three trials on each of four 
consecutive days, followed by a so-called probe trial (PT) 1 h after the last trial on day 4. Additionally, 
all animals had to perform a visual test after the PT on the last day to exclude visual problems as 
reason for behavioural results. 
Descriptive statistical analysis was performed on all evaluated parameters. Data were averaged and 
represented as mean ± standard error of mean (SEM). Outliers detected with Grubb’s test were 
excluded from data analysis. Normality distribution of the values was tested with Kolmogorov 
Smirnov normality distribution test. Differences in MWM learning curves were evaluated by a  
Two-way ANOVA followed by Bonferroni’s post-test. In order not to miss tendencies in the ANOVA, 
unpaired two-tailed t-tests or Mann Whitney tests (if values are not normally distributed) were 
calculated. Vehicle treated animals served as a control for AVCRI104P4 receiving mice. 
3.3.3. Tissue Sampling 
Mice were deeply sedated by standard inhalation anesthesia (Isoba®, Essex, UK), CSF was 
collected and the samples were immediately frozen on dry ice and stored at −80 °C until used for Aβ 
determination. Following transcardial perfusion with 0.9% saline brains were also collected. 
Cerebellum was cut off and frozen and hemispheres were divided. Left hemispheres were frozen until 
used for biochemical analysis; right hemispheres for histological investigations were fixed by 
immersion in a freshly produced 4% mixture of paraformaldehyde/PBS (pH 7.4) for 1 h at room 
temperature, transferred to a 15% sucrose PBS solution until sunk at 4 °C to ensure cryoprotection, 
frozen in liquid isopentane, and stored at −80 °C. 
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3.3.4. Biochemistry 
Brain Protein Extraction 
Left hemi-brain samples without cerebellum of transgenic animals were homogenized and separated 
into 2 fractions, the formic acid (FA) and diethylamine (DEA) fractions. Brain hemispheres were 
homogenized in Tissue Homogenization Buffer (THB) (20 mM Tris HCl pH 7.4, 250 mM sucrose;  
1 mM EDTA; 1 mM EGTA, protease inhibitor cocktail; 1 mL THB per 100 mg brain tissue). For the 
extraction of deposited proteins (FA preparation), 200 µL of the THB-homogenate were mixed with  
440 µL cold FA and sonicated. 400 µL of the mixture was centrifuged for 1 h at 74,200 g at 4 °C and 
210 µL supernatant were neutralized with 4 mL FA neutralization solution (1 M TRIS; 0.5 M 
Na2HPO4; 0.05% NaN3). For the extraction of non-plaque-associated proteins (DEA preparation), 1 mL 
of the THB-homogenate was mixed with 1 mL DEA solution (0.4% DEA; 100 mM NaCl) and 
centrifuged for 1 h at 74,200 g at 4 °C. 1.7 mL supernatant were neutralized with 170 µL DEA 
Neutralization Solution (0.5 M Tris HCl, pH 6.8). 
Determination of Aβ Levels 
In the two different brain homogenate fractions (FA and DEA) and in CSF of each transgenic 
mouse, Aβ38, Aβ40 and Aβ42 levels were measured with a commercially available Aβ-kit from 
Mesoscale Discovery (Rockville, ND, USA). Samples from the brain preparations were analyzed in 
duplicate. Due to the small amount, CSF samples were single analyzed only. Aβ levels were evaluated 
in comparison to peptide standards as ng Aβ per mg brain or ng Aβ per mL CSF.  
3.3.5. Histology 
Sectioning, Immunohistochemistry and Image Analysis 
Seven cryo-sections per medio-sagittal level were sagittally cut at 10 µm slice thickness on a Leica 
CM 3050S cryotome. Brain levels were chosen. The cut of the twelve levels started with a random 
section roughly corresponding to Figure 102 in the morphology atlas “The Mouse Brain” (Paxinos and 
Franklin, 2nd edition; approximately 0.24 mm lateral from midline), then sampling was continued 
uniformly and systematically, always retaining seven slices per level in series and discarding 230 µm 
in between the levels. 
Determination of Plaque Load 
Plaque load was determined with 6E10 primary antibody (BioLegend formerly Covance, Dedham, MA, 
USA, #SIG-39320, 1:1000 for 1 h at room temperature) directed against the human amyloid peptide 
(amino acids 1–16), visualized by a fluorescent secondary antibody (Cy3, Jackson ImmunoResearch 
Laboratories Inc., West Grove, PA, USA) and thioflavin S (Sigma, 0.5% solution) staining against  
β-sheet structures in a double incubation. Additionally to standard protocol steps (drying, washing, 
primary and secondary incubations), slices were blocked with M.O.M blocking kit (Vector Laboratories 
Inc., Burlingame, CA, USA) before primary incubation to minimize unspecific secondary binding. 
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Imaging 
Mosaic images including the whole cortex and hippocampus were recorded on a Zeiss 
AxioImager.Z1 microscope using a high aperture lens and an AxioVision 4.8 software driven 
AxioCam MRm (10× lens NA 0.45, 1× optocoupler, Zeiss, Jena, Germany). 
Evaluation of Amyloid Depositions and Plaque Load 
For determination of histopathological variables a uniform systematic random set of five sagittally cut 
10 µm thick sections (deriving from the five different sagittal levels 2, 4, 7, 9, and 12) per brain were 
labelled and whole slice recordings were evaluated to collect a representative individual mean. Region size 
was measured by manual delineation of the hippocampus or neocortex. Labelings were quantified using 
automated image analysis software in a rater independent quantification (Image Pro Plus, version 6.2). IR 
objects were detected above an adaptive intensity threshold based on 8-bit 256 grey levels, which is defined 
as “mean signal in area of interest (AOI) +1.2× standard deviation of mean signal in AOI”. The level varied 
for the different labelings adjusted to the background fluorescence in the channel. Furthermore detected 
objects had to overcome a minimal size of 7 µm2. All variable values were transported automatedly 
into a “csv” format raw data file together with the image title and included object number, surface area, 
mean and sum signal as well as individual threshold levels. Values were normalized to the invidual 
AOI size for each section and region, the values of the five sections averaged to the one individual mean. 
Statistical Analysis 
Descriptive statistical analysis was performed on all evaluated parameters, Kolmogorov Smirnov tests 
were performed to test normal distribution of data. Data in graphs are represented as mean ± SEM. 
Outliers were detected by Grubbs’ test and were excluded from statistical analyses. Values of the five 
single measurements (from five different levels) per animal were averaged to one value per animal 
(individual mean) and group means were calculated with these averaged values. Group differences 
were calculated by an unpaired, two-tailed T-test. 
3.4. Hepatotoxicity Studies in HepG2 Cells 
In brief, HepG2 cells were cultured in 96-well plates at a density of 25,000 cells per well at 37 °C 
and 5% CO2 in growth medium (MEM, 10% FBS, 1% Penc/Strep, 2 mM glutamine, 1 mM sodium 
pyruvate). After 24 h, AVCRI104P4 and tacrine at the indicated concentrations were applied to the 
cells for a total of 24 h. Cell viability and cellular toxicity were determined according to MTT and LDH 
assays, respectively. Cell viability was determined by the MTT assay using a plate-reader (570 nm). 
MTT solution was added to each well in a final concentration of 0.5 mg/mL. After 2 h the MTT 
containing medium was aspired. Cells were lysed in 3% SDS and the formazan crystals were dissolved 
in i-PrOH/HCl. Optical density was measured with a plate-reader at wavelength 570 nm. Cell survival 
rate is expressed as optical density (OD). Data are shown as percentage of vehicle control. 
Cellular toxicity was determined by the cytotoxicity detection kit (LDH, Roche, Mannheim, 
Germany). The assay was performed according to the manufacturer’s instructions. Optical density was 
measured with a plate-reader at wavelength 492 nm. Data are shown as percentage of vehicle control. 
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4. Conclusions 
In a program directed to the development of disease-modifying anti-Alzheimer compounds, 
AVCRI104P4 recently emerged as a very promising drug candidate by virtue of its in vitro multitarget 
profile, which encompasses a very potent AChE inhibitory activity (low nanomolar range) and 
moderately potent inhibitory activities against BChE, Aβ aggregation, and BACE-1 (submicromolar or low 
micromolar range), as well as brain permeability. Because the potencies of a multitarget compound at 
its different targets may not necessarily have to be in a narrow range, in vivo efficacy studies may help 
to assess the adequate ratio of in vitro activities [19]. In this light, we embarked upon the in vivo 
testing of AVCRI104P4 to ascertain whether the anticholinesterase and anti-amyloid activities found 
in vitro might arise also in vivo. 
In this work, we have scaled up all the synthetic steps leading to multigram amounts of 
AVCRI104P4, necessary to perform the planned in vivo studies. To this end, we have developed a 
novel methodology for the multigram chromatographic resolution of the immediate synthetic precursor 
huprine Y, which affords the required (–)-(7S,11S)-enantiomer with higher efficiency and in higher 
enantiomeric excess than the low scale procedure, previously reported by us [26]. 
In vivo studies have been conducted firstly in two transgenic C. elegans strains expressing Aβ3–42 
or Aβ1–42 either constitutively (CL2006) or upon induction by a temperature shift (CL4176). Interestingly, 
AVCRI104P4 protected in a dose-dependent manner CL4176 nematodes against the paralysis caused 
by Aβ oligomers (IC50 34 μM) and also counteracted the Aβ-induced toxicity in CL2006 worms, albeit 
to a lower extent. These effects are specific and not related to its AChE inhibitory activity as indicated 
by the absence of any protective effect observed with the AChE inhibitor aldicarb. A putative effect on 
Aβ production by BACE-1 inhibition or on Aβ aggregation can be also excluded because, on the one 
hand, CL2006 and CL4176 transgenic worms overexpress Aβ without intervention of BACE-1, and, 
on the other hand, AVCRI104P4 was not able to reduce insoluble Aβ deposits in CL2006 worms. 
To gain further insight into the potential in vivo effects of AVCRI104P4 on amyloid pathology and 
cognition, behavioral, biochemical and histological studies were carried out in a well-established 
mouse model of AD, namely in APPSL transgenic mice. AVCRI104P4, administered orally at a dose of 
40 mg/kg/day for 3 months, led to a significant improvement of the short-term memory in the MWM 
compared with vehicle treated animals on the first training day, in spite of a severe muscular weakness 
displayed by some AVCRI104P4 treated animals. To overcome the problems due to that physical 
handicap, a one-week washout period without any treatment was applied before performing again the 
MWM. Unfortunately, after the washout period, transgenic mice that had received AVCRI104P4 did 
not display improved spatial learning and memory capabilities relative to transgenic controls. The 
observation of a clear cognitive effect while animals were being treated with AVCRI104P4 but the 
absence of positive effects one week after interruption of AVCRI104P4 treatment suggests that the 
potent AChE inhibitory activity that was found in vitro for AVCRI104P4 translates into an efficient 
compensation of the central cholinergic deficit and, hence, into a symptomatic relief, i.e., that 
AVCRI104P4 exerts a purely symptomatic action. A disease-modifying effect by AVCRI104P4 would 
have led to a minor degree of neurodegeneration in treated mice and to a better performance in the 
MWM even after the washout period. The absence of a disease-modifying effect was also evident in 
the biochemical and histological studies, where AVCRI104P4 treated animals had similar levels of Aβ 
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peptides in CSF and brain homogenates, as well as similar amyloid burden in cortex and hippocampus. 
These results suggest that AVCRI104P4 does not interfere either with Aβ production or aggregation. 
In summary, AVCRI104P4 exerts a significant cholinergic cognitive effect in a transgenic mouse 
model of AD but it has no effect on Aβ production (Aβ peptides levels) and aggregation (amyloid 
burden) either in APPSL mice or in C. elegans, contrary to our expectactions in the light of its in vitro 
multitarget profile including inhibition of BACE-1 and Aβ aggregation among other actions. Even 
though the mechanisms that are behind the protective effect of AVCRI104P4 in C. elegans remain 
unclear, observation of only a cholinergic but not an anti-amyloid effect for this compound in transgenic 
mice indicates that, besides a decreased toxicity, an improvement of the anti-amyloid/anticholinesterase 
activity ratio will be necessary in further lead optimization endeavours aimed at deriving a drug 
candidate with potential to modify the natural course of AD. 
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